Treatment of acneiform rash by epidermal growth factor inhibitors with oral tetracyclines;Tratamiento de la erupción acneiforme por inhibidores del factor de crecimiento epidérmico con tetraciclinas orales

Actas Dermo-Sifiliograficas

Volumn 97, Issue 8, 2006, Pages 503-508

  Fernández Guarino, Montse ^a   García, Bibiana Pérez ^a   De La Mora, Isabel Aldanondo Fernández ^a   García Millán, Cristina ^a   López, Pilar Garrido ^a   Olasolo, Pedro Jaén ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Acneiform rash; Epidermal growth factor receptor (EGFR); Tetracyclines

Indexed keywords

CAPECITABINE; CARBOPLATIN; DOCETAXEL; DOXYCYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; INTERLEUKIN 2; OXALIPLATIN; PACLITAXEL; TETRACYCLINE DERIVATIVE;

ACNE; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MALE; RASH; RECURRENCE RISK; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 33845265309     PISSN: 00017310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0001-7310(06)73451-2     Document Type: Article

References (15)

1. Castillo L, Etienne-Grimaldi MC, Fischel JL, Formento P, Magne N, Milano G. Pharmacological background of EGFR targeting. Ann Oncol. 2004;15:1007-12.
2. Nanney LB, Magid M, Stoschek CM, King LE. Comparison of epidermal growth factor distribution in normal human epidermis and epidermal appendages. J Invest Dermatol. 1984;83:385-93.
3. Baselga J. New therapeutic agents targeting the epidermal growth factor receptor. J Clin Oncol. 2000;18:54-9.
4. Lee MW, Seo CW, Kim SW, Yang HJ, Lee HW, Choi JH, et al. Cuttaneous side effects in non-small sell lung cancer patients treated with Iressa (ZD 1839), an inhibitor of the epidermal growth factor receptor. Acta Derm Venereol. 2004;84:23-6.
5. Jacot W, Bessis D, Jorda E, Ychou M, Fabbro M, Pujol JL, et al. Acneiform eruption induced by epidermal growth factor receptor inhibitiors in patients with solid tumours. Br J Dermatol. 2004;151:238-41.
6. Pérez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol. 2004;22:3238-47.
7. Herbst RS, LoRusso PM, Purdom M, Ward D. Dermatological side effects associated with gefitinib therapy: clinical experience ang management. Clin Lung Cancer. 2003;4:366-9.
8. Hidalgo M, Siu LL, Neumunaitis J, Rizzo J, Hammond LA, takimoto C, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanted solid malignancies. J Clin Oncol. 2001;19:3267-79.
9. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor reseptor inhibitors. Ann Oncol. 2005;16:1425-33.
10. Van Doorn R, Kirtsching G, Scheffer E. Follicular and epidermal alterations in patients treated with ZD 1839 (Iressa) an inhibitor of the epidermal growth factor receptor. Br J Dermatol. 2002;147:598-601.
11. Segaert S, Tabernero J, Chosidow O, Dirschaka T, Elsner J, Mancini L, et al. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J Dtsch Dermatol Ges. 2005;3:599-606.
12. Guhl G, González de Arriba A, Daudén E. Efectos cutáneos de los inhibidores del factor de crecimiento epidérmico. Actas Dermosifiliogr. 2006;97:296-310.
13. Sapadin AN, Fleischmajer R. Nonantibiotic properties and their clinical implications. J Am Acad Dermatol. 2006;54:258-65.
14. Clinical Data care 62202-655. Cetuximab & Concomitant-Boost Accelerated RT in Patients With Locally Advanced Oropharynx Squamous Cell Carcinoma. [Actualizado 1 de febrero de 2006]: Disponible en: http://www.clinicaltrials.gov.
15. Herrera-Acosta E, Martín-Ezquerra G, Iglesias M, Umbert P. Erupción acneiforme secundaria a cetuximab. Actas Dermosifiliogr. 2005;96:252-4.